cardiovascular outcome trials in diabetes ppt - 42 Cardiovascular Outcomes Data Pioglitazone The pengertian kadar primary endpoint in the PROactive trial was not improved with pioglitazone A secondary endpoint found use of pioglitazone for about three years in patients with T2D and macrovascular disease eg MI stroke PCI may reduce the risk of allcause mortality nonfatal MI and stroke NNT 50Evidence level A high quality RCT Subgroup After 10 Years and 26 CVOTs Where do We Stand on CV Safety in Diabetes Type 2 diabetes is a major risk factor for cardiovascular disease 12 and the presence of both type 2 diabetes and cardiovascular disease increases the risk of death 3 Evidence that glucose Eligibility criteria liraglu6de 06 Primary outcome T2D with 18 mgc Composite of CV death nonfatal MI A1C 70 standard care or nonfatal stroke Age 50 years with R n4668 Key secondary outcome 1 coexis7ng CV condi7ona or 11 Composite of CV death nonfatal MI Age 60 years with nonfatal stroke revasculariza7on 1 CV Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes Adapted from WittbrodtET et al Generalizability of GLP1 RA Cardiovascular Outcomes Trials Enrollment Criteria to the US Type 2 Diabetes Population Poster presented at the America Diabetes Cardiovascular safety of antidiabetic drugsCardiovascular Outcome trials 12 weeks duration 19 trials 9459 subjects Linagliptin versus placeboactive treatment 122 MACE events MACE HR 078 055 111 CARMELINA Dedicated CV Cardiovascular Outcomes Trials in Type 2 Diabetes Where Do We Go From Cardiovascular disease CVD is the leading cause of mortality and morbidity in patients with type 2 diabetes how does diabetes affect the liver T2D Historical concerns about cardiovascular CV risks associated with certain glucoselowering medications gave rise to the introduction of cardiovascular outcomes trials CVOTs Initially implemented to help monitor the CV safety of glucoselowering drugs in patients with T2D The EMPAREG OUTCOME BI 10773 Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients trial of the SGLT2 inhibitor empagliflozin showed a small but statistically significant 03 A1C reduction at study end similar reductions in systolic 45 mmHg and diastolic 2 mmHg blood pressure and weight 2 kg In this article the authors review the study designs and results of CV outcomes trials conducted with sodiumglucose cotransporter 2 inhibitors and glucagonlike peptide 1 receptor agonists and discuss how these may affect clinical practice Cardiovascular disease CVD is the leading cause of death and morbidity in people with diabetes Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Cardiovascular Outcomes Trials in Patients with Diabetes Issues Fitchett D Zinman B Wanner C et al Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk results of the EMPAREG OUTCOME trial Eur Heart J Cardiovascular Outcome Trials in Type 2 Diabetes What Do They Mean for PDF Cardiovascular Outcomes Trials in Type 2 Diabetes Cardiovascular outcomes trials a paradigm shift in the current Cardiovascular disease is the leading cause of death and complications in patients with type 2 diabetes 1 Recently trials evaluating a sodiumglucose diabetes melitus drugs cotransporter 2 inhibitor empagliflozin
pola makan yang baik untuk penderita diabetes
baker heart and diabetes anda survey
